CABG Medical Announces Approval to Expand Clinical Trials Into Europe

CABG Medical Announces Approval to Expand Clinical Trials Into
Europe 


MINNEAPOLIS, June 3  /PRNewswire-FirstCall/ -- CABG Medical, Inc. (NASDAQ:CABG)
today announced it has received approval from regulatory authorities to
evaluate the Holly Graft System in clinical trials at various centers in
Germany.  The Holly Graft(TM) System, is a drug eluting graft (DEG) for
facilitating a coronary artery bypass procedure.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20050114/CGF013LOGO )

"The approval to begin clinical trials in Germany allows us to begin the
evaluation of our technology in what we believe will be the third largest
worldwide market for the Holly Graft System," said Manny Villafana, Chairman
and CEO.  "The approval to begin clinical trials represents a tremendous
opportunity for CABG Medical to begin working with some of the largest
hospitals in the world and on expanded base of qualified physicians."

The clinical trial is designed to collect and analyze "real-world" clinical
outcomes data for CABG Medical's Holly Graft(TM), a paclitaxel- eluting graft
system in the treatment of patients with coronary artery disease

Also, the Company announced today, that Dr. Peter Tesar of the Prince Charles
Hospital in Brisbane, Australia will be presenting an overview of the Company's
DEG clinical trial program at the Annual Scientific Meeting of the
International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) on
June 4, in New York. The meeting is by invitation only and will be held at the
Marriott Marquis.

About CABG Medical

CABG Medical, Inc. is a medical technology company developing technologies and
therapies to improve the treatment of coronary heart disease by advancing
conventional bypass surgery. We have designed our first product, the Holly
Graft(TM) System, by leveraging our understanding of flow dynamics, material
sciences and drug combinations to create a DEG system.

Safe Harbor

This Press Release contains forward-looking statements that may include
statements regarding intent, belief or current expectations of the Company and
its management. Actual results could differ materially from those projected in
the forward-looking statements as a result of a number of important factors,
including regulatory actions, competition, and management of growth. For a
discussion of these and other risks and uncertainties that could affect the
Company's activities and results, please refer to the Company's filings with
the Securities and Exchange Commission. 

http://www.newscom.com/cgi-bin/prnh/20050114/CGF013LOGO

http://photoarchive.ap.org/

DATASOURCE: CABG Medical, Inc.



CONTACT:  Manny Villafana, Chairman & CEO, or John L. Babitt, President &

COO, both of CABG Medical, Inc., [phone], Fax: [phone]



Web site:  http://www.cabgmedical.com/ 

Copyright